Venus Remedies has bagged additional patent for Vancoplus from US PTO. Vancoplus is an antibiotic adjuvant entity effective in one the most deadly resistance by Methicillin Resistant Staphylococcus Aureus (MRSA). Developed by the Venus Medicine Research Centre (VMRC), the R&D wing of Venus Remedies, Vancoplus is the only solution till date for MRSA with more than nine per cent of success rate.
Dr Manu Chaudhary, Joint managing Director, Venus Remedies said, “The patent is valid till 2032. We have already initiated the process for pre IND meeting with US FDA and we are quite optimistic to get a fast track approval for this product because MRSA is under the list of limited pathogens identified under GAIN act by FDA and Vancoplus falls in that QIDP category.”
Venus Remedies already have product patent for Vancoplus from US PTO, this additional patent with broader coverage for use and method of treatment will be beneficial for the company. The formulation will be commercialised in the US market through technology transfer/outlicensing of exclusive marketing rights route and we are open for such deals.
It took Venus Medicine Research Centre (VMRC) more than seven years to develop this product, which has received an overwhelming response from the medical fraternity in India since it was launched in the country four years ago and is growing with more than 25 per cent CAGR in Indian market.
“In view of the steep rise in the prevalence of MRSA, VRSA and hGISA infections, Vancoplus will be the need of the hour, due to its high potency against these infections and mixed bacterial infection of gram negative and gram positive pathogens. We have developed Vancoplus to address this unmet need,” said Chaudhary.
EP News Bureau – Mumbai